149 related articles for article (PubMed ID: 9324998)
21. WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains.
Ferguson M; Magrath DI; Minor PD; Schild GC
Bull World Health Organ; 1986; 64(2):239-46. PubMed ID: 3017595
[TBL] [Abstract][Full Text] [Related]
22. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
[TBL] [Abstract][Full Text] [Related]
23. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies.
Singer C; Knauert F; Bushar G; Klutch M; Lundquist R; Quinnan GV
J Biol Stand; 1989 Apr; 17(2):137-50. PubMed ID: 2541133
[TBL] [Abstract][Full Text] [Related]
24. Regulation and standardization of IPV and IPV combination vaccines.
Baca-Estrada M; Griffiths E
Biologicals; 2006 Jun; 34(2):159-61. PubMed ID: 16682221
[TBL] [Abstract][Full Text] [Related]
25. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
[TBL] [Abstract][Full Text] [Related]
26. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
27. Antibody responses to antigenic sites 1 and 3 of serotype 3 poliovirus after vaccination with oral live attenuated or inactivated poliovirus vaccine and after natural exposure.
Herremans T; Reimerink JH; Kimman TG; van Der Avoort HG; Koopmans MP
Clin Diagn Lab Immunol; 2000 Jan; 7(1):40-4. PubMed ID: 10618274
[TBL] [Abstract][Full Text] [Related]
28. Strain differentiation of polioviruses with monoclonal antibodies.
Osterhaus AD; van Wezel AL; Stegmann AJ; van Asten JA; Hazendonk AG
Dev Biol Stand; 1984; 57():135-9. PubMed ID: 6098494
[TBL] [Abstract][Full Text] [Related]
29. Antigenic sites on type 2 poliovirus.
Patel V; Ferguson M; Minor PD
Virology; 1993 Jan; 192(1):361-4. PubMed ID: 7685967
[TBL] [Abstract][Full Text] [Related]
30. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
Kersten G; Hazendonk T; Beuvery C
Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.
Osterhaus AD; van Wezel AL; van Steenis B; Drost GA; Hazendonk TG
Intervirology; 1981; 16(4):218-24. PubMed ID: 6177658
[TBL] [Abstract][Full Text] [Related]
32. Strain analysis and epitope mapping of West Nile virus using monoclonal antibodies.
Damle RG; Yeolekar LR; Rao BL
Acta Virol; 1998 Dec; 42(6):389-95. PubMed ID: 10358745
[TBL] [Abstract][Full Text] [Related]
33. Identification of the epitope in human poliovirus type 1 Sabin strain recognized by the monoclonal antibody 1G10 using mimotope strategy.
Bai H; Liu S; Shi S; Lu W; Yang Y; Zhu Y; Zhang Z; Guo H; Li X
J Virol Methods; 2020 Feb; 276():113791. PubMed ID: 31778678
[TBL] [Abstract][Full Text] [Related]
34. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
Dragunsky EM; Ivanov AP; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2006 Sep; 194(6):804-7. PubMed ID: 16941347
[TBL] [Abstract][Full Text] [Related]
35. Detection of mutants in polio vaccine viruses using pooled antipoliovirus monoclonal antibodies.
Horie H; Sato-Miyazawa M; Ota Y; Wakabayashi K; Doi T; Yoshizawa K; Doi Y; Hashizume S
Biologicals; 1999 Sep; 27(3):217-26. PubMed ID: 10652177
[TBL] [Abstract][Full Text] [Related]
36. Mapping of the epitopes of poliovirus type 2 in complex with antibodies.
Bannwarth L; Girerd-Chambaz Y; Arteni A; Guigner JM; Ronzon F; Manin C; Vénien-Bryan C
Mol Immunol; 2015 Oct; 67(2 Pt B):233-9. PubMed ID: 26059753
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
[TBL] [Abstract][Full Text] [Related]
38. Structural studies of virus-antibody immune complexes (poliovirus type I): Characterization of the epitopes in 3D.
Bannwarth L; Girerd-Chambaz Y; Arteni AA; Guigner JM; Lemains J; Ronzon F; Manin C; Vénien-Bryan C
Mol Immunol; 2015 Feb; 63(2):279-86. PubMed ID: 25146483
[TBL] [Abstract][Full Text] [Related]
39. Determination of poliovirus-specific IgA in saliva by ELISA tests.
Ivanov A; Dragunsky E; Ivanova O; Rezapkin G; Potapova S; Chumakov K
J Virol Methods; 2005 Jun; 126(1-2):45-52. PubMed ID: 15847918
[TBL] [Abstract][Full Text] [Related]
40. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
Herremans TM; Reimerink JH; Buisman AM; Kimman TG; Koopmans MP
J Immunol; 1999 Apr; 162(8):5011-8. PubMed ID: 10202050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
